Influenza vaccine

摘要

The present invention relates to monovalent influenza vaccine formulations and vaccination regimes for immunizing against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to monovalent influenza immunogenic compositions comprising an influenza antigen or antigenic preparation thereof from an influenza virus strain being associated with a pandemic outbreak or having the potential to be associated with a pandemic outbreak, in combination with an oil-in-water emulsion adjuvant comprising a metabolizable oil, a sterol and/or a tocopherol such as alpha tocopherol, and an emulsifying agent.

主权项

1. A method for immunizing a human against influenza virus infection, the method comprising:
selecting a human who was previously vaccinated with a monovalent first vaccine composition comprising a low amount of an influenza virus antigen or antigenic preparation from an influenza virus of subtype H2, H5, H6, H7 or H9, in combination with an adjuvant, wherein the low antigen amount does not exceed 15 μg of haemagglutinin (HA) per dose, and wherein said adjuvant is an oil-in-water emulsion comprising squalene and an emulsifying agent; and administering to the selected human a monovalent second vaccine composition comprising an influenza virus antigen or antigenic preparation from a variant of the same influenza virus subtype, wherein the variant comprises an antigenically distinct HA, wherein the second vaccine composition is administered 6-14 months after the human was vaccinated with the first vaccine composition.